期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利用药物遗传学提高药物的安全性和有效性 被引量：1

Using Pharmacogenetics to Improve Drug Safety and Efficacy
下载PDF
导出
摘要 药物遗传学是指根据个人的基因型制定药物治疗方案，人们普遍认为它是个体化用药的第一步。在本期杂志中（见223页），Chasman等报道了3-羟基-3-甲基戊二酰辅酶A还原酶（HGMCR）基因中2个常见的多态现象与普伐他汀疗效降低之间的关系。有人调查了与脂质代谢有关的10个基因中的148个单核苷酸的多态性，发现HGMCR基因中含有2个相关单核苷酸多态性的携带者采用药物治疗后，
作者 Susanne B. Haga Wylie Burke, MD 崔艳丽（译） 赵秀丽（校）
机构地区 The Center for the Advancement of Genomics Department of Medical History and Ethics. University of Washington 不详
出处 《美国医学会杂志（中文版）》 2005年第4期230-232,共3页 The Journal of the American Medical Association(Chinese Edition)
关键词 药物遗传学 单核苷酸多态性 安全性 药物治疗方案 个体化用药 基因型 普伐他汀 多态现象 脂质代谢
分类号 R968 [医药卫生—药理学] R394 [医药卫生—医学遗传学]
  • 相关文献

参考文献28

  • 1Chasman Dl, Posada D, Subrahmanyan L, Cook NR, Stanton VP, Ridker PM. A pharrnacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004;291:2821-2827.
  • 2Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care.N Engl J Med. 2003;348:1556-1564.
  • 3Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277:301-306.
  • 4Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-1205.
  • 5Bates DW, Spell N, Cullen D J, et al. The cost of adverse drug events in hospitalized patients. JAMA. 1997;277:307-311.
  • 6Barnes P J, Woolcock AJ. Difficult asthma. Eur Respir J. 1998;12:1209-1218.
  • 7Mackenzie IS, Brown MJ. Genetic profiling versus drug rotation in the optimisation of antihypertensive treatment. Clin Med. 2002;2:465-473.
  • 8Regaldo A. Inventing the pharmacogenomics business. Am J Health Syst Pharm.1999;56:40-50.
  • 9Lindpainter K. PharmacogeneUcsand pharmacogenomicsin drug discovery and development: an overview. Cl in Chem Lab Med. 2003;41:398-410.
  • 10Oscarson M. Pharmacogenetics of drug metabolizing enzymes: importancefor personalized medicine. Clin Chem Lab Med. 2003;41:573-580.

同被引文献18

  • 1Kupiec TC,Raj V,Vu N.Pharmacogenomics for the forensic toxicologist[J].J Anal Toxicol,2006,30(2):65-72.
  • 2Lai E,Riley J,Purvis I,et al.A 4-Mb high-density single nucleotide polymorphism-based map around human APOE[J].Genomics,1998,54:31-38.
  • 3Rioux JD,Daly MJ,Silverberg MS,et al.Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease[J].Nat Genet,2001,29:223-228.
  • 4Hetherington S,Hughes A,Mosteller M,et al.Genetic variations in the HLA-B region and hypemensitivity reactions to abacavir[J].Lancet,2002,359:1121-1122.
  • 5Jannetto PJ,Wong SH,Gock SB,et al.Pharmacogenomics as molecular autopsy for postmortem forensic toxicology:genotyping cytochrome P450 2D6 for oxycodone eases[J].J Anal ToxicoI,2002,26(7):438--447.
  • 6Jin M,Cock SB,Jannetto PJ,et al.Pharmacogenomics as molecular autopsy for forensic toxicology:genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases[J].J Anal Toxicol,2005,29(7):590-598.
  • 7Koski A,Sistonen J,Ojanper I,et al.CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies[J].Forensic Sci Int,2006,158(2-31:177-183.
  • 8Ingelman-Sundberg M,Oscarson M,McLellan RA.Polymorphic human cytochrome P450 enzymes:An opportunity for individualized drug treatment[J].Trends Pharmacol Sci,1999.20:342-349.
  • 9Nelson DR.Cytochrome P450 and the individuality of species[J].Arch Biochem Biophys,1999,369(1):1-10.
  • 10Johansson I,Lundqvist E,Bertilsson L,et al.Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as acanse ofuhrarapid metabolism ofdebrisoquine[J].Proc Natl Acad Sci USA,1993,90:11825-11829.

引证文献1

美国医学会杂志（中文版）
2005年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部